Are you looking for a growth opportunity? I might have it here for you. We are representing a small publicly traded company which likes you to have a hands on approach to developing programs and overall Infrastructure. This includes a private; public; cloud along with vendors and partner expertise! My client wants to move everything
CytRx, a biopharmaceutical research and development company specializing in oncology, announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).
TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition.